• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.

作者信息

Joffe Steven, Lynch Holly Fernandez

机构信息

From the Department of Medical Ethics and Health Policy, Perelman School of Medicine, and the Leonard Davis Institute of Health Economics, University of Pennsylvania (S.J., H.F.L.), and the Children's Hospital of Philadelphia (S.J.) - all in Philadelphia.

出版信息

N Engl J Med. 2018 Feb 22;378(8):695-697. doi: 10.1056/NEJMp1714054. Epub 2018 Jan 10.

DOI:10.1056/NEJMp1714054
PMID:29320302
Abstract
摘要

相似文献

1
Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.联邦“试用权”立法——对美国食品药品监督管理局公共卫生使命的威胁。
N Engl J Med. 2018 Feb 22;378(8):695-697. doi: 10.1056/NEJMp1714054. Epub 2018 Jan 10.
2
A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.一项徒劳无功的研究：阿比盖尔改善晚期药物可及性联盟不会扩大绝症患者对实验性药物的可及性。
Seton Hall Law Rev. 2009;39(2):559-603.
3
Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.规范药品安全：美国食品药品监督管理局、优先适用权与公众健康。
JAMA. 2009 May 20;301(19):2036-7. doi: 10.1001/jama.2009.680.
4
FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.美国食品药品监督管理局扩大治疗用研究性药物可及性的拟议法规：打着改革幌子的现状。
Food Drug Law J. 2009;64(1):183-223.
5
Promoting Patient Interests in Implementing the Federal Right to Try Act.在实施《联邦试用权法案》中促进患者利益
JAMA. 2018 Sep 4;320(9):869-870. doi: 10.1001/jama.2018.9880.
6
On access and accountability--two Supreme Court rulings on generic drugs.论准入与问责制——最高法院关于仿制药的两项裁决
N Engl J Med. 2013 Aug 22;369(8):696-7. doi: 10.1056/NEJMp1308368. Epub 2013 Aug 7.
7
The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?美国食品药品监督管理局的加速审批程序：制药行业是否有足够的自我监管激励措施？
Am J Law Med. 1999;25(4):543-68.
8
Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.不良药物：处方药、优先购买权与无过错解决方案的可能性。
Rev Law Soc Change. 2012;35(4):793-862.
9
Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.平衡政府监管与药品可及性：2007年2月16日在西顿霍尔大学法学院的演讲
Seton Hall Law Rev. 2007;37(4):929-39.
10
Recent developments help the defense of drug companies in 10b-5 cases.近期的发展态势有助于制药公司在10b-5案件中的辩护。
Food Drug Law J. 1996;51(3):345-53.

引用本文的文献

1
Beyond "Ensuring Understanding": Toward a Patient-Partnered Neuroethics of Brain Device Research.超越“确保理解”：迈向患者参与的脑设备研究神经伦理学
AJOB Neurosci. 2022 Oct-Dec;13(4):241-244. doi: 10.1080/21507740.2022.2126550.
2
A survey of pediatric hematologists/oncologists' perspectives on single patient Expanded Access and Right to Try.一项关于儿科血液科医生/肿瘤医生对单患者扩大使用及“尝试权”观点的调查。
Med Access Point Care. 2021 Apr 19;5:23992026211005991. doi: 10.1177/23992026211005991. eCollection 2021 Jan-Dec.
3
The Randomised Controlled Trial at the Intersection of Research Ethics and Innovation.
研究伦理与创新交叉点的随机对照试验。
Pharmaceut Med. 2022 Oct;36(5):287-293. doi: 10.1007/s40290-022-00438-8. Epub 2022 Jul 25.
4
From "Ought" to "Is": Surfacing Values in Patient and Family Advocacy in Rare Diseases.从“应当”到“是”：罕见病患者及家属权益倡导中的价值彰显
Am J Bioeth. 2021 Dec;21(12):1-3. doi: 10.1080/15265161.2021.1996801.
5
Expanded Access and Right To Try Requests: The Community Oncologist's Experience.扩大准入和尝试权请求：社区肿瘤医生的经验。
JCO Oncol Pract. 2021 Nov;17(11):e1719-e1727. doi: 10.1200/OP.20.00569. Epub 2021 Apr 22.
6
Ethical and legal considerations related to disorders of consciousness.与意识障碍相关的伦理和法律问题。
Curr Opin Pediatr. 2020 Dec;32(6):765-771. doi: 10.1097/MOP.0000000000000961.
7
"I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try.“我认为这已经被忽视了”：肿瘤学家对尝试权的看法和经验。
J Natl Cancer Inst. 2021 Jun 1;113(6):735-741. doi: 10.1093/jnci/djaa137.
8
The Role of the Food and Drug Administration in Drug Development: On the Subject of Proarrhythmia Risk.美国食品药品监督管理局在药物研发中的作用：关于心律失常风险的问题
J Innov Card Rhythm Manag. 2020 Jan 15;11(1):3958-3967. doi: 10.19102/icrm.2020.110103. eCollection 2020 Jan.
9
Expanded Access as a source of real-world data: An overview of FDA and EMA approvals.扩展准入作为真实世界数据的来源：FDA 和 EMA 批准的概述。
Br J Clin Pharmacol. 2020 Sep;86(9):1819-1826. doi: 10.1111/bcp.14284. Epub 2020 Apr 7.
10
Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program.为患有严重或危及生命疾病的患者提供实验性药物治疗：临床试验及美国食品药品监督管理局扩大获取项目指南
Pharmaceut Med. 2019 Apr;33(2):89-98. doi: 10.1007/s40290-019-00274-3.